The FDA Just Authorized Mango and Blueberry Vapes. Sen. Durbin Called It a Gift to Big Tobacco.

In May 2026, the FDA authorized fruit-flavored e-cigarettes — mango, blueberry, and others — for sale in the United States. This is the first time the agency has approved non-tobacco, non-menthol e-cigarette flavors under the premarket authorization pathway that has governed the ENDS market since 2021. In the same month, the FDA issued guidance extending “enforcement discretion” to a broader category of unauthorized flavored e-cigarettes and nicotine pouches, effectively allowing them to stay on store shelves while their applications work through review. The federal government also quietly withdrew a proposed rule that would have banned menthol cigarettes.

The FDA’s stated rationale is coherent as a public health argument: adult cigarette smokers who cannot quit represent an enormous burden of preventable mortality, and flavored nicotine products — with lower combustion toxicity than cigarettes — may be a viable harm reduction tool for adults whose alternative is continued smoking. The authorization framework requires that each product demonstrate its benefit to adult users outweighs its risk of recruiting new nicotine-dependent users, particularly adolescents. The FDA says it applied that standard.

Senator Dick Durbin called it “letting Big Tobacco target children.” STAT News reported that FDA officials who had worked on the prior restrictive approach to flavored products were caught flat-footed by the scope of the reversal. The American Lung Association’s characterization was less diplomatic: the decision “puts youth at risk” by flooding the retail market with products designed to make nicotine initiation more appealing. The enforcement discretion guidance — which lets manufacturers sell non-authorized products without fear of enforcement while under review — is what STAT called a “get out of jail free card.”

The tension here is real, not manufactured. The evidence that flavored e-cigarettes are an effective cessation tool for adult smokers is genuinely mixed; the evidence that they recruit adolescent users at higher rates than tobacco-flavored products is substantially stronger. The FDA’s decision weights one side of that tradeoff. Whether that weighting is correct depends on your priors about who actually uses these products and what they use them for — and the available market data, which STAT has reported on extensively, suggests the “adult cessation” user population is a minority of actual e-cigarette buyers.

What is not in dispute: nicotine addiction is a substance use disorder under the DSM-5, and it kills more Americans than any other substance. The policy environment shaping nicotine dependence in 2026 is now, for the first time, explicitly permissive toward the product formats most associated with adolescent uptake. That’s a clinical fact worth tracking.

Rize Recovery’s substance guides cover nicotine and tobacco dependence. See resources at rizerecovery.com/newsroom/substances/nicotine-tobacco.